EGFR
EGFR(表皮生长因子受体)
EGFR (epidermal growth factor receptor) is the cell-surface receptor of its specific ligands, including epidermal growth factor and TGFα (transforming growth factor α) and is a receptor tyrosine kinase.
EGFR 相关产品(242)
- GC10225Dacomitinib (PF299804, PF299)CAS: 1110813-31-4纯度: >98.00%
A pan-ErbB receptor tyrosine kinase inhibitor
- GC11126Mutant EGFR inhibitorCAS: 1421373-62-7纯度: >99.00%
Mutant EGFR inhibitor 是从专利WO 2013014448 A1中提取的一种有效的选择性突变EGFR抑制剂；抑制 EGFRL858R、EGFRExon 19 缺失和 EGFRT790M。
- GC11892AEE788 (NVP-AEE788)CAS: 497839-62-0纯度: >98.00%
An inhibitor of EGFR and VEGFR tyrosine kinases
- GC12910Canertinib (CI-1033)CAS: 267243-28-7纯度: >99.50%
Canertinib (CI-1033)是一种强效、不可逆的EGFR抑制剂，对EGFR、HER2和HER4的IC 50 值分别为0.8、19和7nM。
- GC13296Afatinib(BIBW2992)CAS: 439081-18-2
Afatinib(BIBW2992)是一种口服、选择性ErbB家族受体酪氨酸激酶（RTK）抑制剂，其对EGFR激酶的IC 50 值为0.05nM，对HER2激酶为14nM，对HER4激酶为1nM。
- GC13761AZD8931 (Sapitinib)CAS: 848942-61-0纯度: >99.50%
A reversible inhibitor of ErbB1/EGFR, ErbB2/HER2, and ErbB3/HER3
- GC13854AG-490 (Tyrphostin B42)CAS: 133550-30-8纯度: >98.00%
AG-490 (Tyrphostin B42)是EGFR抑制剂,IC50为0.1 µM, AG-490对JAK2也有抑制作用。
- GC13873BMS-690514CAS: 859853-30-8纯度: >99.50%
BMS-690514 是一种有效的、具有口服活性的 EGFR 和 VEGFR 抑制剂；对 EGFR、HER 2 和 HER 4 的 IC50 分别为 5、20 和 60 nM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC10225 | Dacomitinib (PF299804, PF299) | 1110813-31-4 | >98.00% | |
A pan-ErbB receptor tyrosine kinase inhibitor | ||||
| GC10362 | Neratinib (HKI-272) | 698387-09-6 | >99.50% | |
A dual inhibitor of EGFR and HER2 | ||||
| GC10627 | Erlotinib | 183321-74-6 | >99.50% / >98.00% | |
Erlotinib是一种有效且口服生物可利用的表皮生长因子受体（EGFR）酪氨酸激酶抑制剂，IC 50 值为2 nM。 | ||||
| GC10944 | Butein | 487-52-5 | >98.00% | |
A plant polyphenol | ||||
| GC11015 | PD168393 | 194423-15-9 | >98.50% | |
An irreversible EGFR kinase inhibitor | ||||
| GC11126 | Mutant EGFR inhibitor | 1421373-62-7 | >99.00% | |
Mutant EGFR inhibitor 是从专利WO 2013014448 A1中提取的一种有效的选择性突变EGFR抑制剂；抑制 EGFRL858R、EGFRExon 19 缺失和 EGFRT790M。 | ||||
| GC11250 | WZ8040 | 1214265-57-2 | >98.00% | |
An inhibitor of mutant EGFR | ||||
| GC11691 | AST-1306 | 897383-62-9 | - | |
An irreversible inhibitor of EGFR, HER2, and HER4 | ||||
| GC11892 | AEE788 (NVP-AEE788) | 497839-62-0 | >98.00% | |
An inhibitor of EGFR and VEGFR tyrosine kinases | ||||
| GC12249 | Varlitinib (ARRY334543) | 845272-21-1 | - | |
An inhibitor of EGFR and HER2 | ||||
| GC12478 | ARRY-380 | 937265-83-3 | - | |
An inhibitor of EGFR | ||||
| GC12837 | Compound 56 | 171745-13-4 | - | |
A potent EGFR inhibitor | ||||
| GC12910 | Canertinib (CI-1033) | 267243-28-7 | >99.50% | |
Canertinib (CI-1033)是一种强效、不可逆的EGFR抑制剂，对EGFR、HER2和HER4的IC 50 值分别为0.8、19和7nM。 | ||||
| GC13091 | CP-724714 | 383432-38-0 | >99.00% | |
A selective HER2/ErbB2 tyrosine kinase inhibitor | ||||
| GC13257 | AC480 (BMS-599626) | 714971-09-2 | - | |
A dual inhibitor of EGFR and HER2 | ||||
| GC13296 | Afatinib(BIBW2992) | 439081-18-2 | - | |
Afatinib(BIBW2992)是一种口服、选择性ErbB家族受体酪氨酸激酶（RTK）抑制剂，其对EGFR激酶的IC 50 值为0.05nM，对HER2激酶为14nM，对HER4激酶为1nM。 | ||||
| GC13608 | Lapatinib | 231277-92-2 | >99.50% | |
Lapatinib是一种口服的双重EGFR和HER2酪氨酸激酶抑制剂，对HER2阳性乳腺癌具有显著疗效。Lapatinib对纯化的EGFR和HER2的半数抑制浓度（IC₅₀）值分别为10.2nM和9.8nM。 | ||||
| GC13761 | AZD8931 (Sapitinib) | 848942-61-0 | >99.50% | |
A reversible inhibitor of ErbB1/EGFR, ErbB2/HER2, and ErbB3/HER3 | ||||
| GC13854 | AG-490 (Tyrphostin B42) | 133550-30-8 | >98.00% | |
AG-490 (Tyrphostin B42)是EGFR抑制剂,IC50为0.1 µM, AG-490对JAK2也有抑制作用。 | ||||
| GC13873 | BMS-690514 | 859853-30-8 | >99.50% | |
BMS-690514 是一种有效的、具有口服活性的 EGFR 和 VEGFR 抑制剂；对 EGFR、HER 2 和 HER 4 的 IC50 分别为 5、20 和 60 nM。 | ||||
| GC14295 | Gefitinib hydrochloride | 184475-55-6 | >99.00% | |
An EGFR inhibitor | ||||
| GC14695 | CO-1686 (AVL-301) | 1374640-70-6 | >99.50% | |
A selective inhibitor of mutant EGFR | ||||
| GC15494 | WZ4002 | 1213269-23-8 | >98.50% | |
A potent inhibitor of EGFR-T790M kinase activity | ||||
| GC15600 | Erlotinib Hydrochloride | 183319-69-9 | >99.50% | |
An EGFR tyrosine kinase inhibitor | ||||